-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, Cinda Biotech (01801.HK) announced that Cindilizumab (European product name: Zybrivo®) has received the first positive opinion from the European Medicines Agency (EMA) Commission for Human Medicines (CHMP). The CHMP recommended approval of cindilizumab combination chemotherapy for adult patients with advanced non-squamous non-small cell lung cancer (NSCLC). If approved by the European Commission, Zybrivo will expand first-line treatment options for lung cancer patients in Europe. Cindilizumab is an immunotherapeutic drug. It is an all-human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1).

智通财经·11/15/2026 23:57:02
语音播报
Zhitong Financial App News, Cinda Biotech (01801.HK) announced that Cindilizumab (European product name: Zybrivo®) has received the first positive opinion from the European Medicines Agency (EMA) Commission for Human Medicines (CHMP). The CHMP recommended approval of cindilizumab combination chemotherapy for adult patients with advanced non-squamous non-small cell lung cancer (NSCLC). If approved by the European Commission, Zybrivo will expand first-line treatment options for lung cancer patients in Europe. Cindilizumab is an immunotherapeutic drug. It is an all-human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1).